Wednesday, 26 August 2026European Markets

IDEX BIOMETRICS Stock Was Up By 16.29% Today

Loading stream...

(VIANEWS) - The Market ended the session with IDEX BIOMETRICS (IDEX.OL) jumping 16.29% to kr0.49 on Wednesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI fell 0.19% to kr1,286.30, following the last session's downward trend on what was a somewhat negative trend trading session today.

IDEX BIOMETRICS's last close was kr0.42, 69.53% below its 52-week high of kr1.37.

About IDEX BIOMETRICS

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-0.22.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -199.48%.

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com